Two Sigma Advisers
LXRX icon

Two Sigma Advisers’s Lexicon Pharmaceuticals LXRX Stock Holding History

Two Sigma Advisers’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-180,977
Closed -$208K – 1226
2025
Q4 		$208K Buy
+180,977
New +$249K ﹤0.01% 2113
2023
Q4 		– Sell
-34,844
Closed -$38K – 2583
2023
Q3 		$38K Buy
+34,844
New +$61.1K ﹤0.01% 2297
2021
Q3 		– Sell
-359,316
Closed -$1.65M – 2583
2021
Q2 		$1.65M Buy
359,316
+294,743
+456% +$1.42M ﹤0.01% 1393
2021
Q1 		$379K Buy
+64,573
New +$447K ﹤0.01% 2127
2020
Q3 		– Sell
-455,816
Closed -$909K – 2542
2020
Q2 		$909K Buy
455,816
+17,900
+4% +$35.1K ﹤0.01% 1619
2020
Q1 		$854K Buy
437,916
+148,200
+51% +$441K ﹤0.01% 1571
2019
Q4 		$1.2M Buy
289,716
+226,100
+355% +$870K ﹤0.01% 1488
2019
Q3 		$191K Buy
63,616
+36,600
+135% +$113K ﹤0.01% 2051
2019
Q2 		$170K Sell
27,016
-9,900
-27% -$59.3K ﹤0.01% 2159
2019
Q1 		$205K Buy
36,916
+8,500
+30% +$51.6K ﹤0.01% 2106
2018
Q4 		$189K Buy
28,416
+12,739
+81% +$103K ﹤0.01% 2144
2018
Q3 		$167K Sell
15,677
-18,200
-54% -$209K ﹤0.01% 2108
2018
Q2 		$407K Buy
33,877
+19,229
+131% +$197K ﹤0.01% 1998
2018
Q1 		$126K Buy
14,648
+4,072
+39% +$37.7K ﹤0.01% 2206
2017
Q4 		$104K Buy
+10,576
New +$110K ﹤0.01% 2146
2017
Q2 		– Sell
-25,105
Closed -$360K – 2328
2017
Q1 		$360K Sell
25,105
-43,648
-63% -$648K ﹤0.01% 2028
2016
Q4 		$951K Sell
68,753
-90,750
-57% -$1.46M ﹤0.01% 1584
2016
Q3 		$2.88M Buy
159,503
+143,317
+885% +$2.31M 0.01% 860
2016
Q2 		$232K Buy
+16,186
New +$220K ﹤0.01% 1814
2015
Q1 		– Sell
-21,373
Closed -$136K – 2182
2014
Q4 		$136K Buy
+21,373
New +$172K ﹤0.01% 2289

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Two Sigma Advisers's LXRX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2026, closing a stake of 180,977 shares — an estimated $208K sold.

Two Sigma Advisers first reported a position in LXRX in Q4 2014 and held it in 20 quarters. The position peaked at $2.88M in Q3 2016. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Two Sigma Advisers reported no remaining Lexicon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 180,977 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $208K.
  • Two Sigma Advisers first reported a position in Lexicon Pharmaceuticals in Q4 2014 and held it in 20 quarters.
  • Two Sigma Advisers's Lexicon Pharmaceuticals position peaked at $2.88M in Q3 2016.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.